Search - tctmd.com

Displaying 41 - 60 of 108

Sort: Relevancy | Date

Presentation AHA 2022

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

Presenter: Michelle L. O’Donoghue

November 07, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

Presentation TCT 2022

TCT 181: Effect of Lipoprotein(a) in Patients With Coronary Calcification Undergoing Percutaneous Coronary Intervention

Presenter: Deshan Yuan

September 18, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT

Caitlin E. Cox

July 08, 2022

News Daily News

AHA Revamps Life’s Simple 7, Adding Sleep to Create ‘Essential 8’

Todd Neale

June 29, 2022

News Conference News EAS 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

Presentation ACC 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

April 04, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Daily News

GRACE Performs Poorly in Ethnic Minorities With NSTEMI, Study Finds

L.A. McKeown

March 01, 2022

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

News Daily News

Cumulative Burden of LDL Cholesterol Increases CHD Risk

Michael O'Riordan

September 23, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Daily News

Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals

Michael O'Riordan

January 16, 2020

Advertisement

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

TCT 181: Effect of Lipoprotein(a) in Patients With Coronary Calcification Undergoing Percutaneous Coronary Intervention

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT

AHA Revamps Life’s Simple 7, Adding Sleep to Create ‘Essential 8’

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

GRACE Performs Poorly in Ethnic Minorities With NSTEMI, Study Finds

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Cumulative Burden of LDL Cholesterol Increases CHD Risk

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content